Xiaomi has sealed a deal to buy some 1,500 patents from Microsoft, a move that will help the Chinese smartphone maker expand exports and earn the US technology giant some badly needed goodwill in Beijing.
The transaction addresses a key weakness facing Xiaomi, which is seeking to sell its devices in countries outside its home market but has been hindered by its relative lack of intellectual property to fend off lawsuits.
“In terms of patents we are a young company,” Xiaomi said on Wednesday, adding that the Microsoft deal is “a big milestone for us. It will help us with operations in new markets.”
The agreement comes on the eve of a visit to Beijing by Microsoft chief executive Satya Nadella. The US company is still the subject of an antitrust investigation in China over bundling of software, with its offices raided by Chinese authorities in July 2014.
The patent deal includes Xiaomi installing Microsoft’s Office and Skype software on its phones. Financial terms were not made public.
Xiang Wang, senior vice-president, said Xiaomi was “excited” to be working with Microsoft and that the deal demonstrated the Chinese company “is looking to build sustainable, long-term partnerships with global technology leaders”.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas